OLN Great Debates 2026: Genitourinary Cancers, New Leadership Join the Spotlight

A single new study can shift your practice, but the hardest part is knowing exactly how to use it for the patient in front of you. In 2026, OLN Great Debates brings that challenge to the stage through expert presentations, real world case controversies, and Q&A. The 2026 meetings take place March 14-15 in Miami and September 26-27 in New York City, with evidence challenged in real time across gastrointestinal, lung, breast, gynecologic, and now genitourinary cancers.

I am honored to serve as Genitourinary Co-Chair as this meeting expands. Ultimately, the goal is to give clinicians clearer judgment, more confidence in their decisions, and guidance they can apply in real patient care.
 

Why the Debate Format Works for Modern Oncology

Solid tumor oncology is moving fast, and many treatment choices now have multiple reasonable options. That is why the oncology event that dares to disagree matters.

When oncology education is built around debate, the evidence is tested in the open. Assumptions get challenged, and the line between clear data and clinical judgment becomes easier to see. You will see experts walk through competing approaches, respond to new data as it emerges, and share how they manage the gray areas that come up in daily practice.

Genitourinary Cancers Take Center Stage in 2026

Genitourinary cancers are in a period of rapid change, with new therapeutic options and increasing complexity across disease areas. The new Genitourinary Cancer focus area is built to help you interpret evolving data and make confident, patient centered decisions in prostate, renal, and bladder cancers. This program brings data, experience, and differing viewpoints into one conversation.

Session topics include:

• First-Line Strategies in Metastatic Renal Cancer: Doublet Immune Checkpoint Blockade vs Immune Checkpoint Blockade Plus VEGFR TKI
• Optimizing Immunotherapy Strategies in Muscle-Invasive Bladder Cancer: Neoadjuvant IO-Containing Systemic Therapy vs Risk-Adapted Adjuvant IO
• Using Lutetium-PSMA in Metastatic Prostate Cancer: Early vs Later Use

Clinicians work through the real questions behind treatment choices, and each debate tests the evidence in clear, practical ways. Q&A and case discussion reveal where the data is strong and where judgment still matters, giving you takeaways that fit directly into your daily practice.

What You Can Apply Right Away After Attending

• Sharper clinical judgment by seeing how experts weigh evidence when options conflict
• More confident treatment planning through debate on sequencing, selection, and real-world application
• Better patient conversations because you will understand the tradeoffs behind competing approaches
• Actionable takeaways that reflect modern practice, not idealized trial populations
   

Event Details: OLN Great Debates 2026

• March 14-15 | Miami
• September 26-27 | New York City
• Website
• Registration
   

Matthew Galsky, MD, is Professor of Medicine (Hematology and Medical Oncology), Director of Genitourinary Medical Oncology, Co-Director of the Center of Excellence for Bladder Cancer; The Tisch Cancer Institute.